FDA Approves Tremfya for Moderate to Severe Plaque Psoriasis – P&T Community

Posted: July 19, 2017 at 3:44 am

FDA Approves Tremfya for Moderate to Severe Plaque Psoriasis
P&T Community
The FDA has approved guselkumab (Tremfya, Janssen Biotech) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first approved biologic therapy that selectively ...

Read more from the original source:
FDA Approves Tremfya for Moderate to Severe Plaque Psoriasis - P&T Community

Related Posts